Centro de Investigación Biomédica en Red de Cáncer-ko ikertzaileekin lankidetzan egindako argitalpenak (11)

2024

  1. Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology

    Scientific Reports, Vol. 14, Núm. 1

  2. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

2022

  1. Response to Mobocertinib in a patient with advanced Non-Small Cell Lung Cancer harboring EGFR exon 20 insertion after several therapies including Amivantamab

    Current Problems in Cancer: Case Reports, Vol. 5

2021

  1. ALK rearranged non–small cell lung carcinoma with EML4-NTRK3 fusion as a possible mechanism of resistance to third-generation ALK inhibitors

    Current Problems in Cancer: Case Reports, Vol. 4

  2. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

2020

  1. Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2020), 22, 6, (823-834), 10.1007/s12094-019-02211-x)

    Clinical and Translational Oncology

  2. Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 22, Núm. 6, pp. 823-834

2019

  1. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance

    Lung Cancer, Vol. 134, pp. 72-78

  2. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

    Annals of Oncology, Vol. 30, Núm. 2, pp. 290-296

2018

  1. Aligning digital CD8 + scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma

    Histopathology, Vol. 72, Núm. 2, pp. 270-284

  2. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

    The Lancet Respiratory Medicine, Vol. 6, Núm. 10, pp. 771-781